Anti-PD-L1 Therapy Failed to Reduce the Risk of Developing Brain Metastases in Patients with ES-SCLC

被引：0
|
作者：
Lu, S. [1 ]
Guo, X. [1 ]
Li, Y. [1 ]
Liu, H. [1 ]
Zhang, Y. [1 ]
Zhu, H. [1 ]
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Extensive-stage small cell lung cancer (ES-SCLC); PD-L1 checkpoint inhibitors; Brain metastases (BMs);
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.17-04
引用
收藏
页码：S379 / S380
页数：2
相关论文
共 50 条
  • [1] Outcomes of First-Line Anti-PD-L1 Blockades Combined with Brain Radiotherapy (BRT) for Extensive-Stage SmallCell Lung Cancer (ES-SCLC) with Brain Metastases (BM)
    Tian, Y.
    Ma, J.
    Zhu, H.
    Yu, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E360 - E360
  • [2] Dual PD-L1 and CTLA4 inhibition in ES-SCLC
    David Killock
    Nature Reviews Clinical Oncology, 2021, 18 (2) : 64 - 64
  • [3] Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China
    Zhou, Dongchu
    Dong, Xinrui
    Zhou, Zhen
    Liu, Qiao
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2023, 16 : 2521 - 2529
  • [4] Outcomes of anti-PD-L1 blockades plus etoposide and platinum (EP) as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC) with brain metastasis (BM).
    Tian, Yaru
    Ma, Ji
    Zhu, Hui
    Yu, Jinming
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Biomarkers for Predicting the Efficacy of PD-L1 Inhibitors Combined with Chemotherapy in ES-SCLC
    Sun, Y.
    Liu, R.
    Ai, X.
    Lu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S369 - S370
  • [6] Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
    Jiming Chen
    Jie Yang
    Wenhui Wang
    Danfeng Guo
    Chengyan Zhang
    Shibo Wang
    Xinliang Lu
    Xiaofang Huang
    Pingli Wang
    Gensheng Zhang
    Jing Zhang
    Jianli Wang
    Zhijian Cai
    Cellular & Molecular Immunology, 2022, 19 : 1290 - 1301
  • [7] Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
    Chen, Jiming
    Yang, Jie
    Wang, Wenhui
    Guo, Danfeng
    Zhang, Chengyan
    Wang, Shibo
    Lu, Xinliang
    Huang, Xiaofang
    Wang, Pingli
    Zhang, Gensheng
    Zhang, Jing
    Wang, Jianli
    Cai, Zhijian
    CELLULAR & MOLECULAR IMMUNOLOGY, 2022, 19 (11) : 1290 - 1301
  • [8] The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
    Tunger, Antje
    Sommer, Ulrich
    Wehner, Rebekka
    Kubasch, Anne Sophie
    Grimm, Marc-Oliver
    Bachmann, Michael Philipp
    Platzbecker, Uwe
    Bornhaeuser, Martin
    Baretton, Gustavo
    Schmitz, Marc
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (10)
  • [9] Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy
    Schaberg, Kurt B.
    Novoa, Roberto A.
    Wakelee, Heather A.
    Kim, Jinah
    Cheung, Christine
    Srinivas, Sandhya
    Kwong, Bernice Y.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2016, 43 (04) : 339 - 346
  • [10] Pulmonary Sarcoidosis Associated With Anti-Pd-L1 Therapy
    Balestra, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
12345